Scarica l'app Stockscreener
0.413
0.98%
0.004
Pre-mercato:
.40
-0.013
-3.15%
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
RSI Check: Will Ensysce Biosciences Inc benefit from geopolitical trends2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 - Nasdaq
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial - Investing.com Nigeria
Does Ensysce Biosciences Inc. meet Warren Buffett’s criteriaEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Ensysce Biosciences CEO says 'positioned for continued momentum' - MSN
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial By Investing.com - Investing.com South Africa
New Highs: Does JPMPRM outperform in volatile marketsTrade Volume Report & Stock Timing and Entry Methods - baoquankhu1.vn
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Ensysce Flat on Review News - Baystreet.ca
Opioid designed to stay inactive until swallowed hits Phase 3 milestone - stocktitan.net
Rate Hike: Will The Western Union Company benefit from geopolitical trendsBond Market & Fast Gain Stock Tips - baoquankhu1.vn
Merger Talk: Is Ensysce Biosciences Inc stock showing strong momentumQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Ensysce Biosciences receives patent allowance in Brazil for pain tech By Investing.com - Investing.com Canada
Ensysce Biosciences receives patent allowance in Brazil for pain tech - Investing.com
New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
What sentiment indicators say about Ensysce Biosciences Inc. stockBreakout Watch & Stock Portfolio Risk Management - ulpravda.ru
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - Улправда
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - Улправда
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Can Ensysce Biosciences Inc. stock resist market sell offsQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
MarketsMedicine Hat News - FinancialContent
New ADHD drug designed to deter abuse and overdose wins EU patent - Stock Titan
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsSell Signals and Alerts & Low Cost Trading Plans - Улправда
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - FinancialContent
ENSC: All proposals passed and clinical programs advanced, setting the stage for a pivotal year - TradingView — Track All Markets
Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch - TipRanks
Ensysce Biosciences Issues Annual Shareholder Letter - The Globe and Mail
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid By Investing.com - Investing.com India
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid - Investing.com
Inside a biotech developing pain pills with built-in overdose protection - Stock Titan
Ensysce Biosciences Secures $4M Financing for PF614 - MSN
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 188.9% in December - Defense World
Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда
How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда
Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда
Ensysce Biosciences Earnings Notes - Trefis
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):